The RK-1 continuous mixing processor from Readco Kurimoto is suited for testing formulations in continuous processing conditions.
Courtesy Readco
Process equipment manufacturer Readco Kurimoto introduced the RK-1 continuous mixing processor, which incorporates the company's proprietary mixing technology in a compact, tabletop unit. The company states that the unit was developed to help product development professionals test new and existing formulations being processed in batches using a continuous process in a controlled, laboratory environment. Scaled down to process 10 lbs/hr, the RK-1 combines heat transfer, mixing, and shear to process multiple powdered, liquid, and viscous ingredients in a single step, while yielding a high quality, homogeneous product at discharge that meets targeted specifications for moisture, texture, color, uniformity, and other criteria.
The novel RK-1 features twin shaft, co-rotating screws with a one-inch diameter set within a closed barrel to promote the intimate contact among wet and dry materials needed to achieve the desired level of mixing, blending, reacting, crystallization, and/or encapsulation. Suitable for use in research and development laboratories for pharmaceuticals and other products, the versatile RK-1 includes touch-screen controls for setup, monitoring, and real-time adjustments. Other available options include a mobile lift table, electric band heater, feed chute, and all-stainless steel construction.
The RK-1 continuous processors are engineered and manufactured in the company's York, PA headquarters. The lab-size processors operate on 220 volts single-phase and are delivered ready to plug in and operate.
Source: Readco
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.